Coherus Biosciences | CHRS - Equity Capital And Reserves


Coherus Biosciences reported $60.84M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Fujifilm JPY 3.84T 119.25B Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026
Zoetis USD 3.15B 85M Jun/2026